IRON-I.C. Trial
Cross-source consensus on IRON-I.C. Trial from 1 sources and 6 claims.
1 sources · 6 claims
Dosage & preparation
Comparisons
Other
Other
Other
Highlighted claims
- IRON-I.C. is a single-centre, randomized, open-label, crossover phase I–II pilot study in an ICU in France. — Evaluation of the performance and safety of adding the iron chelator MEX-CD1 to dialysate during continuous veno-venous haemodialysis for removing excess labile iron in intensive care patients with sepsis-associated acute kidney injury - the Iron in Intensive Care trial (IRON-I.C.): protocol for a p
- The trial plans to enroll fourteen adult ICU patients with sepsis-associated AKI requiring renal replacement therapy. — Evaluation of the performance and safety of adding the iron chelator MEX-CD1 to dialysate during continuous veno-venous haemodialysis for removing excess labile iron in intensive care patients with sepsis-associated acute kidney injury - the Iron in Intensive Care trial (IRON-I.C.): protocol for a p
- Participants serve as their own controls in a two-period crossover design comparing MEX-CD1-supplemented dialysate with standard dialysate. — Evaluation of the performance and safety of adding the iron chelator MEX-CD1 to dialysate during continuous veno-venous haemodialysis for removing excess labile iron in intensive care patients with sepsis-associated acute kidney injury - the Iron in Intensive Care trial (IRON-I.C.): protocol for a p
- The intervention uses two consecutive 24-hour CVVHD sessions with identical RRT parameters. — Evaluation of the performance and safety of adding the iron chelator MEX-CD1 to dialysate during continuous veno-venous haemodialysis for removing excess labile iron in intensive care patients with sepsis-associated acute kidney injury - the Iron in Intensive Care trial (IRON-I.C.): protocol for a p
- MEX-CD1 is administered at 50 mg/L in CiCa dialysate without dose escalation. — Evaluation of the performance and safety of adding the iron chelator MEX-CD1 to dialysate during continuous veno-venous haemodialysis for removing excess labile iron in intensive care patients with sepsis-associated acute kidney injury - the Iron in Intensive Care trial (IRON-I.C.): protocol for a p
- After the intervention phase, further dialysis required for care uses standard dialysate only. — Evaluation of the performance and safety of adding the iron chelator MEX-CD1 to dialysate during continuous veno-venous haemodialysis for removing excess labile iron in intensive care patients with sepsis-associated acute kidney injury - the Iron in Intensive Care trial (IRON-I.C.): protocol for a p